Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Exp Mol Pathol ; 94(1): 84-90, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23000426

RESUMO

The primo vascular system (PVS), which is composed of very small primo-vessels (PV) and primo-nodes (PN), has recently emerged as a third component of circulatory system. Here, we report the presence of a tumor derived PVS in murine xenografts of human histiocytic lymphoma (U937) in close proximity to the tumor. Within this system, PNs are small (~500-600 µM diameter) membranous sac-like structures which contain numerous small cells which can be demonstrated by DAPI staining. Hematoxylin and Eosin (H&E) staining of the peri-tumoral PVS shows the presence of loose structures lined by fibroblasts but filled with dense fibers, cells, lacunae and nerve-like structures. The origin and type of cells within the PVS was characterized by immunostaining with antibodies for CD68, CD45 and lysozyme. The results of these studies reveal that the PVS of the xenograft originates from the human U937 tumor cells. qRT-PCR analysis of mRNA isolated from PVS cells reveals a striking predominance of human, rather than mouse, sequences. Of particular interest, human stem cell specific transcription factors were overexpressed, most notably KLF4, an upstream regulator of NANOG which maintains the pluripotent and undifferentiated state of stem cells. These results suggest that the cells present within the PVS are derived from the human xenograft and suggests that the primo-vessels associated with the xenografted tumor may provide a safe haven for a select population of cancer stem cells. Further understanding of the biological properties of these cells may allow the development of new anti-cancer interventions.


Assuntos
Linfoma Difuso de Grandes Células B/patologia , Células-Tronco Neoplásicas , Animais , Antígenos CD/análise , Antígenos de Diferenciação Mielomonocítica/análise , Linhagem Celular Tumoral , Humanos , Fator 4 Semelhante a Kruppel , Fatores de Transcrição Kruppel-Like/metabolismo , Antígenos Comuns de Leucócito/análise , Antígenos Comuns de Leucócito/imunologia , Meridianos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Muramidase/metabolismo , Transplante de Neoplasias , Células-Tronco Neoplásicas/metabolismo , RNA Mensageiro/análise , Nicho de Células-Tronco , Transplante Heterólogo , Células U937
2.
Nutr Cancer ; 63(8): 1256-62, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22043833

RESUMO

The incidence of esophageal adenocarcinoma in humans is increasing more rapidly than any other malignancy in the United States. Animal studies have demonstrated the efficacy of freeze-dried berry supplementation on carcinogen-induced esophageal squamous cell carcinoma in rats; however, no such studies have been done in esophagoduodenal anastomosis (EDA), an animal model for reflux-induced esophageal adenocarcinoma (EAC) development. Eight-week-old male Sprague-Dawley rats were randomized into 3 groups: EDA + control diet (EDA-CD; n = 10); EDA + 2.5% black raspberry diet (EDA-BRB; n = 11) and EDA + 2.5% blueberry diet (EDA-BB; n = 12). After 2 wk of feeding the respective diets, the rats underwent EDA surgery to induce gastroesophageal reflux and then continued the diet. Measurement of feed intake suggested that all EDA-operated animals had lower feed intake starting at 10 wk after surgery and this was significant close to termination at 24 wk. There were no significant differences in either reflux esophagitis (RE), intestinal metaplasia (IM) (70% in CD, 64% in BRB, and 66% in BB; P = 0.1) or EAC incidence (30% for CD, 34% for BRB, and 25% for BB; P = 0.2) with supplementation. Berry diets did not alter COX-2 levels, but BB diet significantly reduced MnSOD levels (1.23 ± 0.2) compared to control diet (2.05 ± 0.14; P < 0.05). We conclude that a dietary supplementation of freeze-dried BRB and BB at 2.5% (w/w) was not effective in the prevention of reflux-induced esophageal adenocarcinoma in this EDA animal model.


Assuntos
Suplementos Nutricionais , Neoplasias Esofágicas/tratamento farmacológico , Esofagite Péptica/patologia , Esôfago/efeitos dos fármacos , Frutas/química , Preparações de Plantas/farmacologia , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/prevenção & controle , Anastomose Cirúrgica , Animais , Antocianinas/análise , Ácido Ascórbico/análise , Biomarcadores/análise , Mirtilos Azuis (Planta)/química , Ciclo-Oxigenase 2/efeitos dos fármacos , Ciclo-Oxigenase 2/genética , Ciclo-Oxigenase 2/metabolismo , Modelos Animais de Doenças , Progressão da Doença , Neoplasias Esofágicas/prevenção & controle , Esofagite Péptica/tratamento farmacológico , Esofagite Péptica/prevenção & controle , Esôfago/patologia , Manipulação de Alimentos/métodos , Liofilização/métodos , Modelos Lineares , Masculino , Ratos , Ratos Sprague-Dawley , Selênio/análise , Superóxido Dismutase/efeitos dos fármacos , Superóxido Dismutase/genética , Superóxido Dismutase/metabolismo , Aumento de Peso/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA